Shaperon Inc. (KOSDAQ:378800)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,922.00
0.00 (0.00%)
At close: Feb 19, 2026
Market Cap88.65B -24.9%
Revenue (ttm)179.38M +96.6%
Net Income-14.59B
EPS-541.21
Shares Out46.24M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,230,569
Average Volume1,178,184
Open1,886.00
Previous Closen/a
Day's Range1,870.00 - 1,990.00
52-Week Range1,580.00 - 4,120.00
Beta0.11
RSI52.41
Earnings DateNov 14, 2025

About Shaperon

Shaperon Inc. develops therapies based on GPCR19-inflammasome inhibitor platform and NanoMab antibody platform for immune diseases. It offers NuGel which blocks the root cause of atopic dermatitis that is in Phase 2 clinical trials; NuDifin that calms wound inflammation and accelerates the regeneration of tissue; NuRalin indicated for atopic dermatitis; NuAreatin for the treatment of alopecia areata. The company also provides NuCerin, a pill designed to reduce neuroinflammation; NuSepin, which alleviates excessive systemic inflammation; and NuP... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 378800
Full Company Profile

Financial Performance

In 2024, Shaperon's revenue was 17.70 million, a decrease of -91.77% compared to the previous year's 215.25 million. Losses were -14.90 billion, 20.2% more than in 2023.

Financial Statements